

INDEX TO VOLUME 17

AUTHOR INDEX

- Adatia, A., 341
 Agarwal, N., 267, 455
 Alapiessa, U., 19
 Almonte, H., 195
 Amenomori, Y., 41
 Anandalaxmi, P.M., 341
 Arimura, A., 61, 283
 Åstedt, B., 531
 Atienza, M.F., 513
 Atterfelt, P., 183
 Aznar, R., 153
 Ballard, C.A., 383
 Bard, D.S., 443
 Barros, C., 87
 Basu, R., 163
 Beck, L.R., 253
 Bergquist, C., 537
 Bhatnagar, S., 341
 Björn-Rasmussen, E., 183
 Buhi, W.C., 71
 Burkman, R.T., 513
 Burton, F.G., 221
 Bustos-Obregón, E., 87
 Chandra, V.L., 341
 Chantler, E.N., 35
 Chatterjee, A., 163, 407, 547
 Ciaccio, L.A., 231
 Croxatto, H.B., 553
 Das, R.P., 413
 Daunter, B., 27, 35
 Dericks-Tan, J.S.E., 79
 Devi, P.K., 375
 Driskell, J.A., 499
 Duenhoelter, J.H., 51
 Dumbaugh, V.S., 71
 Duncan, G.W., 221
 Duncan, L.J.P., 291
 Eberlein, L., 79
 Elstein, M., 35
 Erkkola, R., 580
 Forte, K., 383
 Fotherby, K., 365
 Fujimoto, S., 41
 Gaitan, J.R., 195
 Gallegos, A.J., 153
 Ganguly, M., 1
 Goel, V., 341
 González, J., 87
 Gordon, N.R., 221
 Goyal, V., 375
 Gresser, J.D., 253
 Guizer, E., 153
 Gullberg, B., 563
 Gupta, M., 407
 Gupta, T., 547
 Hagbard, L., 355
 Hamberger, L., 183
 Haspels, A.A., 141
 Heald, P.J., 329
 Hemphill, P., 465
 Hernandez, A.B., 195
 Herrera, E., 87
 Hill, J.L., 231
 Hingorani, V., 103, 267, 341, 455
 Howe, G.R., 309
 Howes, J.F., 253
 Hudson, R., 465, 475, 489
 Hümpel, M., 207
 Hyman, M.J., 309
 Ingemanson, C.-A., 355
 Ishihama, A., 41
 Jagannatha, K.T., 267, 455
 Jain, A.K., 267
 Jeyaseelan, S., 103
 Johansson, E.D.B., 131
 Joshi, U.M., 375
 Kalkwarf, D.R., 221
 Kalla, N.R., 523
 Kemp, W.R., 93
 Killian, G.J., 93
 Kincl, F.A., 231
 King, T.M., 513
 Kinra, G., 103, 267, 455
 Kobayashi, T., 41
 Krishna, U., 341

CONTRACEPTION

INDEX TO VOLUME 17


AUTHOR INDEX (CONTINUED)

- | | |
|-----------------------------|------------------------------|
| Kwon, H.Y., 237 | Reno, F., 489 |
| Lähteenmäki, P., 9, 115, | Rivera, R., 195 |
| 169, 297, 569 | Ross, A., 247 |
| Lauersen, N.H., 383 | Ross, J.A., 237 |
| Laumas, K.R., 103, 267, 341 | Roy, S., 315 |
| Leong, P., 475 | Ruiz, R., 195 |
| Liedholm, P., 531, 563 | Sakamoto, S., 41 |
| Liukko, P., 580 | Saxena, B.N., 365 |
| Lobl, T.J., 123 | Schally, A.V., 61, 283 |
| Luukkainen, T., 115, | Sciarra, J.J., 435 |
| 169, 569 | Sekiba, K., 41 |
| Macdonald, P.C., 51 | Ser, K., 163 |
| Mahan, C.S., 71 | Shimizu, T., 41 |
| Mandleker, A., 341 | Shrimanker, K., 365 |
| Matsuda, S., 41 | Siddiqui, U.A., 329 |
| Matsuyama, E., 41 | Singh, B., 523 |
| Merino, G., 153 | Sivin, I., 575 |
| Milewich, L., 51 | Sjöberg, N.-O., 531, 563 |
| Mishell, D.R., Jr., 315 | Skiens, W.E., 221 |
| Moore, D.E., 315 | Smith, R.P., 247 |
| Naik, V.K., 375 | Sorbe, B., 355 |
| Nakanishi, T., 41 | Soza, X., 553 |
| Navarro, C.L., 195 | Speck, U., 207 |
| Nillius, S.J., 537 | Spellacy, W.N., 71 |
| Nilsson, C.G., 9, 115, 569 | Spence, M.R., 513 |
| Nilsson, L., 183 | Srivastava, K., 531 |
| Nilsson, S., 131 | Stanczyk, F.Z., 315 |
| Notelovitz, M., 443 | Steel, J.M., 291 |
| Nummi, S., 19 | Streb, C., 79 |
| Nygren, K.-G., 131 | Sunouchi, S., 41 |
| Osser, S., 563 | Suzuki, M., 41 |
| Pedroza, E., 61, 283 | Swisher, D., 475 |
| Pharriss, B.B., 489 | Takada, M., 41 |
| Pommerenke, G., 207 | Takkar, D., 103, 341 |
| Porteus, S.E., 123 | Tangney, C.C., 499 |
| Pulkkinen, P., 423 | Taubert, H.-D., 79 |
| Purandare, V.N., 341 | Tillson, S.A., 465, 475, 489 |
| Puri, C.P., 267 | Valles, J., 195 |
| Quijada, S., 553 | van den Bergh, A.S., 141 |
| Rahman, S.A., 267 | Veal, J.T., 221 |
| Ramos, R.S., 51 | Vihko, R., 19 |
| Ranta, T., 19 | Viinikka, L., 19 |

INDEX TO VOLUME 17

AUTHOR INDEX (CONTINUED)

- | | |
|-----------------------------|----------------------|
| Vilchez-Martinez, J.A., 61, | Wendt, H., 207 |
| 283 | WHO, 395 |
| Virker, K.D., 341 | Wide, L., 537 |
| Virkkunen, P., 19 | Wiqvist, N., 183 |
| Wagatsuma, T., 41 | Wise, D.L., 253 |
| Wan, L.S., 1 | Yadav, H.S., 341 |
| Watson, J., 329 | Yanagimachi, R., 413 |
| Weiss, C., 207 | Ylikorkala, O., 19 |
| Weiss, G., 1 | Zatuchni, G.I., 435 |



CONTRACEPTION

INDEX TO VOLUME 17

SUBJECT INDEX

- Abortifacient effectiveness, single 15-me-PGF₂ α methyl ester vaginal suppository, 383
- Abortion, urea amniocentesis, bacteriologic culture results, 513
- Antifertility activity, 5-thio-D-glucose, male (mouse, rat), 123
- Antifertility efficacy, PMSG (rat), 547
- Assay of long-acting contraceptive steroid formulations (rabbit), 365
- Autonomic drugs, vaginally deposited, influence on fertility (rabbit), 309
- Bacteriologic culture, effect of midtrimester urea abortion, 513
- Birth control, use of stimulatory LH-RH analogue, 537
- Bleeding control, norethisterone-releasing IUD, 115
- Bleeding pattern,
 comparative clinical evaluation of injectable NET-OEN and DMPA, 395
 d-norgestrel silastic capsules, 315
- Bromocriptine, effect upon pituitary stimulation by LH-RH and TRH, 79
- Cervical mucus,
 effect of norethisterone, 35
 levels of disulphide and sulphydryl groups, 35
 scanning electronmicroscopy, 27
 sialic acid levels, 27
 trace metal content, 35
- α - chlorohydrin,
 effect on glycosidase activity in epididymal epithelial cells (rat), 93
 effect on male fertility (hamster), 413
 effect on phospholipid analysis in testis-epididymis complex (rat), 523
- Clinical evaluation, single silastic implant-D containing norethindrone acetate, 341
- Clinical experience with FD-1 IUD, 41
- Clinical study, single 15(S)15-methyl-PGF₂ α methyl ester vaginal suppository, 267
- Combined oral contraceptive pill, serious complications in insulin-dependent diabetics, 291
- Comparative clinical evaluation, multinational, injectable NET-OEN and DMPA, 395
- Complications, oral contraception in insulin-dependent diabetics, 291
- Conjugated estrogen, post-ovulatory interceptive, 443

CONTRACEPTION

- Contraceptive effects, progesterone-releasing IUD (rabbit), 465
- Copper beads, intraoviductal, effect on fertility (rabbit), 553
- Copper IUD,
 - early postpartum insertion, 355
 - menstrual blood loss, 153
 - pelvic inflammatory disease, 563
- Copper T, immediate post-abortion insertion, 237
- Cortisone, reversal of antifertility efficacy of PMSG (rat), 547
- Cu-7 IUD, sialic acid levels in cervical mucus, 27
- Cu-7-Gravigard, early postpartum insertion, 355
- Cu-T-200, early postpartum insertion, 355
- Dalkon Shield,
 - immediate post-abortion insertion, 237
 - sialic acid levels in cervical mucus, 27
- Danazol (17 α -pregn-4-en-20-yno(2,3-d) isoxazol-17-ol),
 - effect on gonadotropin basal levels, male (rat), 61
 - effect on gonadotropin secretion after ovariectomy (rat), 283
 - effect on pituitary responsiveness to LH-RH, male (rat), 61
- Depot-medroxyprogesterone acetate (DMPA)
- Diabetics, insulin-dependent, serious complications of oral contraception, 291
- Dimethyl polysiloxane (silastic^R)
- Disulphide and sulphhydryl groups, cervical mucus, 35
- DMPA (depot-medroxyprogesterone acetate)
- Early abortion by vaginal PG suppositories, 183
- Early postpartum insertion of copper IUD, 355
- Early pregnancy interruption, use of silastic device containing 15-Me-PGF₂ α , 51
- Early pregnancy termination, single dose (15(S)15 methyl PGF₂ α methyl ester vaginal suppository, 455
- Embryology, progesterone-releasing IUD (rabbit), 489
- Endometrial histology, effect of norethindrone acetate implant, 103
- Endometrium, effect of progesterone-releasing IUD on fibrinolytic activity, 531
- Epididymal epithelial cells, effect on glycosidase activity by α -chlorohydrin (rat), 93
- Ergocornine methanesulphonate, blockade of ovulation (rat), 407
- Estradiol, plasma level, effect of U11,100A and U11,555A (rat), 329
- Estradiol cyclopentylpropionate, luteolytic efficacy (rat), 163
- Estradiol level, immediate postabortal contraception with ethinylestradiol + d-norgestrel, 297
- Estradiol pattern, d-norgestrel silastic capsules, 315
- Estradiol-17 β level following abortion by 15(S)15-methyl-PGF₂ α -methyl ester suppositories, 183

CONTRACEPTION

- Estrogen, conjugated, use as post-ovulatory interceptive, 443
- Estrogen and female fertility (rat), 163
- Ethinyl estradiol,
 - level in human milk and plasma after oral administration, 131
 - plasma concentration, immediate postabortal contraception, 9
 - radioimmunoassay method in human milk, 131
- Ethinyl estradiol + megestrol acetate, level in human milk and plasma, 131
- Ethinyl estradiol + norgestrel, pituitary response to LH-RH stimulation, 1
- Ethinylestradiol + d-norgestrel,
 - elimination of HCG, 169
 - immediate postabortal contraception, 9
 - microdose, immediate postabortal contraception, 169, 297
 - suppression of pituitary and ovarian function, 169
- Ethinyl estradiol + dl-norgestrel, post-coital contraception, 247
- Evaluation of fertilizing capacity of human spermatozoa, penetration of foreign eggs, 87
- Fabrication of vaginal contraceptive devices, progestogen-releasing, 221
- FD-1 IUD, clinical experience, 41
- Female sterilization reversal, report of workshop, 435
- Fertility, influence of vaginally deposited autonomic drugs (rabbit), 309
- Fertility inhibition, intraoviductal copper beads, 553
- Fertilizing capacity of human spermatozoa, evaluation by penetration of foreign eggs, 87
- Fibrinolytic activity of endometrium, effect of progesterone-releasing IUD, 531
- First-pass effect, consideration during investigations of levonorgestrel, 207
- Foreign egg penetration, evaluation of fertilizing capacity of human spermatozoa, 87
- Glycosidase activity, effect of α -chlorohydrin treatment, male (rat), 93
- Gonadotropin basal levels, effect of Danazol, male (rat), 61
- Gonadotropin level, immediate postabortal contraception with ethinylestradiol + d-norgestrel, 297
- Gonadotropin secretion, effect of Danazol after ovariectomy (rat), 283
- HCG (human chorionic gonadotropin)
- HCG elimination, effect of immediate postabortal contraception with ethinylestradiol + d-norgestrel, 169
- HCG elimination in relation to blood loss, 15(S)15-methyl-PGF₂ α -methyl ester vaginal suppositories, 183

CONTRACEPTION

- Hematocrit, effect of Lippes IUD, 195
- Hemoglobin, effect of Lippes IUD, 195
- Hormonal study, single 15(S)15-methyl-PGF₂ α methyl ester vaginal suppository, 267
- Human chorionic gonadotropin (HCG)
- Immediate postabortal contraception, microdose ethinyl-estradiol + d-norgestrel, 169, 297
- Immediate post-abortion IUD insertion, 237
- Immediate postabortal oral contraception, plasma concentrations of ethinylestradiol and d-norgestrel, 9
- Implant, norethindrone acetate, endometrial histology and progesterone levels, 103
- Indomethacin,
 - reversal of antifertility efficacy of PMSG (rat), 547
 - reversal of luteolytic efficacy of estradiol cyclopentylpropionate (rat), 163
- Inhibition of ovulation, use of stimulatory LH-RH analogue, 537
- Injectable, long-acting gestagen formulations, assay (rabbit), 365
- Injectable NET-OEN and DMPA, comparative clinical evaluation, 395
- Injectable sustained release norethisterone system (baboon), 253
- Interceptive, post-ovulatory, use of conjugated estrogen, 443
- Interruption of early pregnancy, use of silastic device containing 15-Me-PGF₂ α , 51
- Intraoviductal copper beads, effect on fertility (rabbit), 553
- Intrauterine device (IUD),
 - copper, 355
 - copper T, 153, 237
 - Cu-7, 27
 - Dalkon Shield, 27, 237
 - early postpartum insertion, 355
 - FD-1, 41
 - immediate post-abortion insertion, 237
 - levonorgestrel-releasing, 153
 - Lippes, 195
 - Lippes loop, 237
 - Lippes loop D, 153
 - menstrual blood loss, 153
 - norethisterone-releasing, 115, 153
 - d-norgestrel-releasing, 569
 - pelvic inflammatory disease, 563
 - plasma prolactin level, 71
 - progesterone-releasing, 153, 531
 - progesterone-releasing (rabbit), 465, 475, 489
 - sialic acid levels in cervical mucus, 27
 - TCu 200, 563
- Intravaginal administration, PGF₂ α -methylester suppositories, mid-trimester abortion, 141

- Iron and iron binding capacity, serum, effect of Lippes IUD, 195
- IUD (intrauterine device)
- Levonorgestrel, investigation of pharmacokinetics, 207
- Levonorgestrel-releasing IUD, menstrual blood loss, 153
- LH-RH (luteinizing hormone releasing hormone),
 - analogue, stimulatory, effect on ovulation, 537
- LH-RH stimulation, pituitary response during oral contraceptive therapy, 1
- Lippes IUD, effect on hemoglobin, hematocrit, serum iron and iron binding capacity, 195
- Lippes loop, immediate post-abortion insertion, 237
- Lippes loop D, menstrual blood loss, 153
- Long-acting contraceptive steroid formulations, assay (rabbit), 365
- Luteinizing hormone releasing hormone (LH-RH),
 - effect of bromocriptine upon pituitary stimulation, 79
 - effect of oral contraceptives upon pituitary stimulation, 79
 - pituitary response during Danazol treatment after ovariectomy (rat), 283
 - pituitary responsiveness during Danazol treatment, male (rat), 61
- Luteolytic efficacy of estradiol cyclopentylpropionate (rat), 163
- Male antifertility agent,
 - α -chlorohydrin, 93, 413, 523
 - Danazol, 61, 283
 - monothioglycerol, 413
 - 5-thio-D-glucose, 123, 413
- Male fertility, effects of monothioglycerol, α -chlorohydrin and 5-thio-D-glucose (hamster), 413
- Male sterilization reversal, report of workshop, 435
- 15-Me-PGF₂ α ((15S)-15-methyl prostaglandin F₂ α methyl ester)
- 15-Me-PGF₂ α methyl ester (15(S)-15-methyl-prostaglandin F₂ α methyl ester)
- Mechanisms of action, progesterone-releasing IUD (rabbit), 475
- Medroxyprogesterone acetate, blood level of injectable formulation (rabbit), 365
- Medroxyprogesterone acetate, injectable,
 - bleeding patterns, 395
 - multinational comparative clinical evaluation, 395
 - side effects, 395
- Menstrual blood loss, IUDs, 153
- Mestranol + norethindrone,
 - effect on vitamin E status, 499
 - pituitary response to LH-RH stimulation, 1
- Mid-trimester abortion, intravaginal administration of PGF₂ α -methylester suppositories, 141
- Milk, human, ethinyl estradiol level after oral administration, 131

CONTRACEPTION

- Mitotic patterns of uterus in early pregnancy, effect of U11,100A and U11,555A (rat), 329
- Monothioglycerol, effect on male fertility (hamster), 413
- Multinational comparative clinical evaluation, injectable NET-OEN and DMPA, 395
- NET-OEN (norethisterone oenanthate)
- Norethindrone, circulating levels, single silastic implant containing norethindrone acetate, 375
- Norethindrone acetate,
clinical evaluation of single silastic implant-D, 341
single silastic implant, circulating levels of norethindrone, 375
- Norethindrone acetate implant, endometrial histology and progesterone levels, 103
- Norethindrone-releasing silicone rubber vaginal devices, 221
- Norethisterone,
effect on disulphide and sulphydryl groups in cervical mucus, 35
effect on trace metal content in cervical mucus, 35
injectable sustained release system (baboon), 253
plasma level with norethisterone-releasing IUD, 115
- Norethisterone oenanthate (NET-OEN),
blood level of injectable formulation (rabbit), 365
- Norethisterone oenanthate, injectable,
bleeding patterns, 395
multinational comparative clinical evaluation, 395
side effects, 395
- Norethisterone-releasing IUD,
influence on ovarian function, 115
menstrual blood loss, 153
plasma levels norethisterone, 115
- Norgestrel pelargonate, blood level of injectable formulation (rabbit), 365
- d-Norgestrel,
plasma concentration, immediate postabortal contraception, 9
plasma concentrations during use of d-norgestrel-releasing IUD, 569
serum level with d-norgestrel silastic capsules, 315
silastic capsules, bleeding and serum d-norgestrel, estradiol and progesterone patterns, 315
- d-Norgestrel-releasing IUD, plasma concentrations of d-norgestrel, 569
- d-Norgestrel-releasing silicone rubber vaginal devices, 221
- dl-Norgestrel + ethinyl estradiol, post-coital contraception, 247
- Oral contraception,
immediate postabortal, plasma concentrations of ethinylestradiol and d-norgestrel, 9
immediate postabortal microdose ethinylestradiol + d-norgestrel, 297

CONTRACEPTION

- serious complication in insulin-dependent diabetics, 291
- Oral contraceptives,
 - effect on vitamin E status, 499
 - effect upon pituitary response by LH-RH and TRH, 79
 - ethinyl estradiol in human milk and plasma, 131
 - pituitary response to LH-RH stimulation, 1
 - plasma prolactin level, 71
- Org 2154 (16 α -ethyl-21-hydroxy-19-nor-pregn-4-ene-3,20-dione-21-dodecanoate),
 - blood level of injectable formulation (rabbit), 365
- Org 3236 (3-ethyl-11-methylene-18,19-dinor-17 α -pregn-4-en-20-yn-3-one),
 - effect on pituitary-ovarian function, 19
- Ovarian function,
 - influence by norethisterone-releasing IUD, 115
 - suppression by immediate postabortal contraception with ethinylestradiol + d-norgestrel, 169
- Ovariectomy, effect of Danazol on gonadotropin secretion (rat), 283
- Ovulation, effect of stimulatory LH-RH analogue, 537
- Ovulation blockade, ergocornine methanesulphonate (rat), 407
- Oxidized spermine (N,N¹-bis(3-propionaldehyde)1,4-diaminobutane),
 - specific inhibition of spermatozoal energy metabolism, 423
- Parity, effect on pelvic inflammatory disease during IUD use, 563
- Pelvic inflammatory disease, effect of parity during IUD use, 563
- Penetration of foreign eggs, evaluation of fertilizing capacity of human spermatozoa, 87
- PG (prostaglandin)
- PGF₂ α -methylester suppositories, mid-trimester abortion induced by intravaginal administration, 141
- Pharmacokinetic investigations, levonorgestrel, 207
- Phospholipid analysis, effect on testis-epididymis complex after α -chlorohydrin (rat), 523
- Pituitary function, suppression by immediate postabortal contraception with ethinylestradiol + d-norgestrel, 169
- Pituitary response to LH-RH, effect of Danazol after ovariectomy (rat), 283
- Pituitary response to LH-RH stimulation, oral contraceptive therapy, 1
- Pituitary responsiveness to LH-RH, effect of Danazol, male (rat), 61
- Pituitary-ovarian function, effect of Org 3236, 19
- PMSG (pregnant mare's serum gonadotropin)

CONTRACEPTION

- Postabortal,
 - immediate ethinylestradiol + d-norgestrel, 9
 - immediate IUD insertion, 237
 - immediate microdose ethinylestradiol + d-norgestrel, 169, 297
- Post-coital contraception, ethinyl estradiol + dl-norgestrel, 247
- Post-ovulatory interceptive, conjugated estrogen, 443
- Postpartum, early, insertion of copper IUD, 355
- Preclinical evaluation of intrauterine progesterone as a contraceptive agent (rabbit), 465, 475, 489
- Pregnant mare's serum gonadotropin (PMSG), antifertility efficacy (rat), 547
- Progesterone, reversal of ergocornine blockade of ovulation (rat), 407
- Progesterone levels,
 - effect of norethindrone acetate implant, 103
 - effect of U11,100A and U11,555A (rat), 329
 - following abortion by 15(S)15-methyl-PGF₂ α -methyl ester suppositories, 183
 - immediate postabortal contraception with ethinyl-estradiol + d-norgestrel, 297
- Progesterone pattern, d-norgestrel silastic capsules, 315
- Progesterone-releasing IUD,
 - effect on fibrinolytic activity of endometrium, 531
 - embryology and toxicology (rabbit), 489
 - local contraceptive effects and their reversal (rabbit), 465
 - menstrual blood loss, 153
 - possible mechanisms of action (rabbit), 475
- Progesterone-releasing silicone rubber vaginal devices, 221
- Progestogen-releasing silicone rubber vaginal devices, 221
- Prolactin,
 - plasma level during oral contraception, 71
 - plasma level during use of IUDs, 71
- Prostaglandin (PG),
 - PGF₂ α -methylester vaginal suppositories, 141
 - 15(S)15-methyl-PGF₂ α methyl ester, single vaginal suppository, 267, 383, 455
 - 15(S)15-methyl-PGF₂ α -methyl ester vaginal suppositories, 183
 - silastic device containing 15-Me-PGF₂ α , 51
- Prostaglandin concentration, plasma, single 15-Me-PGF₂ α methyl ester vaginal suppository, 383
- Quinacrine hydrochloride, toxic effects (rodents), 231
- Radioimmunoassay method, ethinyl estradiol in human milk, 131
- Reversal of sterilization, male and female, report of workshop, 435
- Reversible sterilization devices, male and female, report of workshop, 435

- (15S)-15-methyl prostaglandin F₂α methyl ester (15-Me-PGF₂α)
- 15(S)-15-methyl-prostaglandin F₂α methyl ester (15-me-PGF₂α methyl ester),
 - abortifacient effectiveness of single vaginal suppository, 383
 - early abortion by vaginal suppositories, 183
 - plasma prostaglandin concentration, single vaginal suppository, 383
 - vaginal suppositories, blood loss in relation to elimination of serum HCG, 183
 - vaginal suppository, clinical and hormonal studies, 267
 - vaginal suppository, single dose schedule, 455
- Scanning electronmicroscopy, cervical mucus, 27
- Second trimester abortion, 15(S)-15-methyl-PGF₂α methyl ester vaginal suppository, 267
- Sialic acid levels in cervical mucus, 27
- Side effects, comparative clinical evaluation of injectable NET-OEN and DMPA, 395
- Silastic^R (dimethyl polysiloxane)
- Silastic capsules of d-norgestrel, bleeding and serum d-norgestrel, estradiol and progesterone patterns, 315
- Silastic device containing 15-Me-PGF₂α,
 - efficacy in inducing abortion, 51
 - interruption of early pregnancy, 51
 - mode of action, 51
- Silastic implant containing norethindrone acetate, circulating levels of norethindrone, 375
- Silastic implant-D containing norethindrone acetate, clinical evaluation, 341
- Silicone rubber vaginal devices, progestogen-releasing, 221
- Single dose schedule, 15(S)15 methyl PGF₂α methyl ester vaginal suppository, 455
- Single 15(S)15-methyl-PGF₂α methyl ester vaginal suppository, clinical and hormonal studies, 267
- Single silastic implant containing norethidnrone acetate, circulating levels of norethindrone, 375
- Single silastic implant-D containing norethindrone acetate, clinical evaluation, 341
- Specific inhibition of spermatozoal energy metabolism by oxidized spermine, 423
- Spermatozoa, human, fertilizing capacity evaluated by penetration of foreign eggs, 87
- Spermatozoal energy metabolism, specific inhibition by oxidized spermine, 423
- Sterilization reversal, male and female, report of workshop, 435


CONTRACEPTION

- Stimulatory LH-RH analogue, effect on ovulation, 537
- Subdermal polysiloxane capsules, d-norgestrel, 315
- Subdermal single silastic implant, norethindrone acetate, 375
- Subdermal single silastic implant-D containing norethindrone acetate, clinical evaluation, 341
- Suppositories,
 PGF₂ α -methylester, mid-trimester abortion induced by intravaginal administration, 141
- vaginal, 15(S)15-methyl-PGF₂ α -methyl ester for early abortion, 183
- Suppository, single vaginal insertion of 15(S)15-methyl-PGF₂ α methyl ester, 267, 383, 455
- Sustained release norethisterone system, injectable (baboon), 253
- Testing of vaginal contraceptive devices, progestogen-releasing, 221
- Testis-epididymis complex, effect on phospholipid analysis after α -chlorohydrin (rat), 523
- 5-Thio-D-glucose,
 antifertility activities, male (mouse, rat), 123
- effect on male fertility (hamster), 413
- Thyrotropin releasing hormone (TRH),
 effect of bromocriptine upon pituitary stimulation, 79
- effect of oral contraceptives upon pituitary stimulation, 79
- Toxic effects of quinacrine hydrochloride (rodents), 231
- Toxicology, progesterone-releasing IUD (rabbit), 489
- Trace metal content, cervical mucus, 35
- TRH (thyrotropin releasing hormone)
- U11,100A and U11,555A,
 effect on plasma hormones (rat), 329
- effect on uterine mitoses in early pregnancy (rat), 329
- Urea abortion, bacteriologic culture results, 513
- Uterine mitoses in early pregnancy, effect of U11,100A and U11,555A (rat), 329
- Vaginal contraceptive devices, fabrication and testing, 221
- Vaginal suppositories of 15(S)15-methyl-PGF₂ α -methyl ester, early abortion, 183
- Vaginal suppository, single insertion of 15(S)15-methyl-PGF₂ α methyl ester, 267, 383, 455
- Vaginally deposited autonomic drugs, influence on fertility (rabbit), 309
- Vitamin E status, effect of oral contraceptives, 499

Volume 17 1978
January - June
ISSN 0010 - 7824

CONTRACEPTION

AN INTERNATIONAL JOURNAL



DANIEL R. MISHELL, Jr., M.D. — Editor

Publisher: GERON-X, INC., LOS ALTOS, CALIF.

BOARD OF ASSOCIATE EDITORS

Wendy Baldwin, Ph.D.
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Gerald S. Bernstein, Ph.D., M.D.
Associate Professor
Department of Obstetrics and
Gynecology
USC School of Medicine
Los Angeles, California 90033

M. C. Chang, Ph.D., Sc.D.
Senior Scientist
Worcester Foundation for
Experimental Biology
Shrewsbury, Massachusetts 01545

Philip A. Corfman, M.D.
Director of Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Uwe Goebelsmann, M.D.
Director of the Reproductive
Endocrinology Laboratory
Women's Hospital
1240 North Mission Road
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.
Director, Division of Clinical
Sciences
Southwest Foundation for
Research and Education
San Antonio, Texas 78228

Roy O. Greep, Ph.D.
Director
Laboratory of Human Reproduc-
tion & Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.
Research Professor
Departments of Pharmacology
and Obstetrics and Gynecology
George Washington University
Medical Center
Washington, D.C. 20037

William D. Odell, M.D.
Professor and Chairman
Department of Medicine
Harbor General Hospital
U.C.L.A. School of Medicine
Torrance, California 90509

C. Alvin Paulsen, M.D.
Professor of Medicine
Department of Medicine
University of Washington
School of Medicine
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.
Chief of Staff
Prentice Women's Hospital and
Maternity Center
333 East Superior St.
Chicago, Illinois 60611

Sheldon Segal, Ph.D.
Director, Biomedical Division
The Population Council
Rockefeller University
York Avenue and 66th Street
New York, New York 10021

William N. Spellacy, M.D.
Professor and Chairman
Department of Obstetrics and
Gynecology
The University of Florida
College of Medicine
Gainesville, Florida 32610

Howard J. Tatum, Ph.D., M.D.
Associate Director
Biomedical Division
The Population Council
The Rockefeller University
New York, New York 10021

Corresponding Editors for CONTRACEPTION

Elsimar Coutinho, M.D.
Professor
Department of Biochemistry and
Obstetrics
University of Bahia
Salvador, Bahia, BRAZIL

P. Giorgio Crosignani, M.D.
Professor Incaricato di
Endocrinologia Ginecologica
alla Facoltà di Medicina
Dell Università di Milano
20122 Milano, ITALY
Via Commenda 12

Egon Diczfalussy, M.D.
Professor
Reproductive Endocrinology
Research Unit
Swedish Medical Research Council
Karolinska Sjukhuset,
Stockholm 60, SWEDEN

J. Ferin, M.D.
Professor
Physiology of Human Reproduction
Research Unit
University of Louvain Hospital
Louvain, BELGIUM

Carlos Gual, M.D.
Instituto Nacional de la Nutrición
Hospital de Enfermedades de la
Nutrición
Av. San Fernando y
Viaducto Tlalpan
MEXICO 22, D.F., MEXICO

I. Hallbrecht, M.D.
Professor
Department of Obstetrics and
Gynecology
Tel Aviv University Medical School
Tel Aviv, ISRAEL

Prof. Dr. J. Hammerstein
Abt. Gynaek. Endokrinologie
Sterilität und Familienplanung
Freie Universität Berlin
Hindenburgdamm 30
1000 Berlin 45
FEDERAL REPUBLIC GERMANY

Professor Doctor A. A. Haspels
Department of Obstetrics and
Gynecology
Academic Hospital
University of Utrecht
Catharijnesingel 101
Utrecht, NETHERLANDS

Tapani Luukkainen, M.D.
Steroid Research Laboratory
University of Helsinki
Department of Medical Chemistry
Siltavuorenpenger 10 A
SF-00170 Helsinki 17, FINLAND

John R. Newton, M.B.
Department of Obstetrics and
Gynecology
King's College Hospital Medical
School
University of London
Denmark Hill
London, SE5 8RX
ENGLAND

Dr. M. R. N. Prasad
Professor of Zoology
University of Delhi
Delhi 7, INDIA

Dr. (Mrs.) Shanta S. Rao
Reproductive Physiology Unit
Indian Council of Medical Research
Seth G. S. Medical College
Parel, Bombay 12, INDIA

Rodney P. Shearman
Professor of Obstetrics and
Gynecology
The University of Sydney
Sydney 2006, NSW
AUSTRALIA

Sabita Tejuja, M.D.
Deputy Director General
Contraceptive Testing Unit
Indian Council of Medical Research
Ansari Nagar
Post Box 4508
New Delhi- 110016
INDIA

Martin P. Vessey, M.D.
Professor, University Department of
Social and Community Medicine
University of Oxford
8 Keble Road
Oxford, OX1 3QN
ENGLAND

Juan Zanartu, M.D.
Associate Professor
Department of Experimental
Fertility
Universidad de Chile Clínica
Obstétrica
Hospital "Jose Joaquín Aguirre"
Casilla 6637
Santiago, CHILE

CONTRACEPTION

January 1978

Volume 17, Number 1

Pituitary Response to LHRH Stimulation in Women on Oral Contraceptives L.S. Wan, G. Weiss and M. Ganguly	1
Plasma Concentrations of Ethinylestradiol and D-Norgestrel during Two Immediate Postabortal Oral Contraceptive Cycles P. Lähteenmäki and C. G. Nilsson	9
Effects of a New Oral Progestagen on Pituitary-Ovarian Function L. Viinikka, S. Nummi, O. Ylikorkala, P. Virkkunen, T. Ranta, U. Alapiessa and R. Vihko	19
Sialic Acid Levels and Scanning Electronmicroscopy of Cervical Mucus B. Daunter	27
The Effect of a Low Dose Progestagen on the Trace Metal Content and Disulphide and Sulphydryl Groups in Cervical Mucus B. Daunter, E. N. Chantler and M. Elstein	35
A Study on the Contraceptive Effectiveness of a Newly Designed IUD "FD-1" in Japan T. Wagatsuma, S. Sakamoto, E. Matsuyama, Y. Amenomori, T. Kobayashi, M. Takada, S. Matsuda, S. Fujimoto, T. Shimizu, M. Suzuki, A. Ishihama, T. Nakanishi, S. Sunouchi and K. Sekiba	41
Interruption of Early Pregnancy with a Silastic Device Containing (15S)-15-Methyl Prostaglandin F _{2α} Methyl Ester: Efficacy and Mode of Action Johann H. Duenhoelter, Rigoberto Santos Ramos, Leon Milewich and Paul C. Macdonald	51
Danazol Effects on Gonadotropin Basal Levels and Pituitary Responsiveness to LH-RH in Immature Male Rats E. Pedroza, J. A. Vilchez-Martinez, A. Arimura and A. V. Schally	61
Plasma Prolactin Levels and Contraception: Oral Contraceptives and Intrauterine Devices William N. Spellacy, Charles S. Mahan, William C. Buih and Virginia S. Dumbaugh	71
The Effect of Oral Contraceptives and of Bromocriptine upon Pituitary Stimulation by LH-RH and TRH J. S. E. Dericks-Tan, L. Eberlein, C. Streb and H.-D. Taubert	79
Fertilizing Capacity of Human Spermatozoa Evaluated by Actual Penetration of Foreign Eggs C. Barros, J. González, E. Herrera and E. Bustos-Obregón	87
Glycosidase Activity in Epididymal Epithelial Cells Isolated from Normal and α -Chlorohydrin Treated Male Rats W. R. Kemp and G. J. Killian	93

CONTRACEPTION is published monthly by Geron-X, Inc.
Box 1108, Los Altos, California 94022, USA.

© 1978, Geron-X, Inc.

Two Volumes per year

Personal Subscription

\$ 60

Institutional Subscription

\$100

Add \$7 for surface postage outside USA

Add \$16 for airmail USA. Add \$36 for airmail outside USA

Second-class postage paid at Los Altos, Calif. 94022, and at additional mailing office.

CONTRACEPTION

February 1978

Volume 17, Number 2

- Endometrial Histology and Progesterone Levels in Women Using Norethindrone
Acetate Implants for Contraception
D. Takkar, S. Jeyaseelan, G. Kinra, K. R. Laumas and V. Hingorani103
- Contraception with a Norethisterone-Releasing IUD. Plasma Levels of Norethisterone
and Its Influence on the Ovarian Function
C. G. Nilsson, T. Luukkainen and P. Lähteenmäki115
- Antifertility Activities of 5-Thio-D-Glucose in Mice and Rats
T. J. Lobl and S. E. Porteus.123
- Ethinyl Estradiol in Human Milk and Plasma after Oral Administration
Staffan Nilsson, Karl-Gösta Nygren and Elov D. B. Johansson.131
- Mid-Trimester Abortion Induced by Intravaginal Administration of
Prostaglandin F₂ α -Methylester Suppositories
A. S. van den Bergh and A. A. Haspels141
- Intrauterine Devices and Menstrual Blood Loss: A Comparative Study of Eight
Devices During the First Six Months of Use
Alfredo J. Gallegos, Ramon Aznar, Guillermina Merino and Elda Guizer . . .153
- Estrogen and Female Fertility. II. Indomethacin and the Reversal of the Luteolytic
Efficacy of Estradiol Cyclopentylpropionate
Amar Chatterjee, Kakoli Sen and Rita Basu163
- Immediate Postabortal Contraception with a Microdose Combined Preparation:
Suppression of Pituitary and Ovarian Function and Elimination of HCG
P. Lähteenmäki and T. Luukkainen.169
- Early Abortion by Vaginal Prostaglandin Suppositories: Blood loss in relation to
elimination of serum chorionic gonadotrophin, progesterone and estradiol-17 β
L. Hamberger, L. Nilsson, E. Björn-Rasmussen, P. Atterfelt
and N. Wiqvist.183

CONTRACEPTION

March 1978

Volume 17, Number 3

- Effect of the Lippes IUD on the Circulating Levels of Hemoglobin,
Hematocrit, Serum Iron and Iron Binding Capacity in Normal Women
Roberto Rivera, Jose R. Gaitan, Cesar L. Navarro, Juan Valles,
Hector Almonte, Rosario Ruiz and Ana B. Hernandez195
- Investigations of Pharmacokinetics of Levonorgestrel to Specific Consideration
of a Possible First-Pass Effect in Women
M. Hümpel, H. Wendt, G. Pommerenke, Chr. Weiss and U. Speck207
- Fabrication and Testing of Vaginal Contraceptive Devices Designed for Release
of Prespecified Dose Levels of Steroids
F. G. Burton, W. E. Skiens, N. R. Gordon, J. T. Veal,
D. R. Kalkwarf and G. W. Duncan221
- Observation on Toxic Effects of Quinacrine Hydrochloride (in Rodents)
Leonard A. Ciaccio, James L. Hill and Fred A. Kincl231
- Post-Abortal Immediate IUD Insertion: Further Experience and a Controlled
Comparison of Three Devices
John A. Ross and Ho Youn Kwon237
- Post-Coital Contraception Using dl-Norgestrel/Ethinyl Estradiol Combination
R. Percival Smith and Adrianne Ross247
- Larger Animal Testing of an Injectable Sustained Release Fertility Control System
Joseph D. Gresser, Donald L. Wise, Lee R. Beck and John F. Howes253
- Clinical and Hormonal Studies with 3 mg 15(S)15-Methyl-PGF_{2a} Methyl Ester
Long-Acting Single Vaginal Suppository
K. T. Jagannatha, C. P. Puri, G. Kinra, N. Agarwal, A. K. Jain,
S. A. Rahman, K. R. Laumas and V. Hingorani267
- Effects of Danazol on Gonadotropin Secretion after Ovariectomy in Rats
J. A. Vilchez-Martinez, E. Pedroza, A. Arimura and A. V. Schally 283

CONTRACEPTION

April 1978

Volume 17, Number 4

Serious Complications of Oral Contraception in Insulin-Dependent Diabetics Judith M. Steel and L. J. P. Duncan	291
Immediate Postabortal Contraception with a Microdose Combined Preparation: Gonadotropin, Estradiol and Progesterone Levels during the Last Treatment Cycle and after Discontinuation of Oral Contraceptives Pekka Lähteenmäki	297
Influence of Vaginally Deposited Autonomic Drugs upon Fertility in the Rabbit Mathew J. Hyman and George R. Howe	309
Bleeding and Serum d-Norgestrel, Estradiol and Progesterone Patterns in Women Using d-Norgestrel Subdermal Polysiloxane Capsules for Contraception Donald E. Moore, Subir Roy, Frank Z. Stanczyk and Daniel R. Mishell, Jr.	315
Effect of U11,100A and U11,555A on Plasma Hormones and Uterine Mitoses in Early Pregnancy in the Rat U.A. Siddiqui, J. Watson and P.J. Heald	329
Long-Term Contraception by a Single Silastic Implant-D Containing Norethindrone Acetate in Women: A Clinical Evaluation D. Takkar, P.N. Anandalaxmi, V.L. Chandra, S. Bhatnagar, H.S. Yadav, K.R. Laumas and V. Hingorani; U. Krishna, A. Mandleker and V.N. Purandare; V. Goel, A. Adatia and K.D. Virker.	341
Early Postpartum Insertion of Copper IUD L. Hagbard, C.-A. Ingemanson and B. Sorbe	355
Assay of Long-Acting Contraceptive Steroid Formulations in Rabbits K. Fotherby, K. Shrimanker and B.N. Saxena.	365
Circulating Levels of Norethindrone in Women with a Single Silastic Implant V. Goyal, U.M. Joshi, V.K. Naik, and P.K. Devi	375
Plasma Prostaglandin Concentration and Abortifacient Effectiveness of a Single Insertion of a 3 mg 15(S)-Methyl-Prostaglandin F _{2α} Methyl Ester Vaginal Suppository Charles A. Ballard, Katherine Forte and Niels H. Lauersen	383
Announcement	393

CONTRACEPTION

May 1978

Volume 17, Number 5

Multinational Comparative Clinical Evaluation of Two Long-Acting Injectable Contraceptive Steroids: Norethisterone Oenanthate and Medroxyprogesterone Acetate.	
2. Bleeding Patterns and Side Effects	
World Health Organization Task Force on Long-Acting Systemic Agents for the Regulation of Fertility	395
Blockade of Ovulation by Ergocornine in Rats and Its Reversal by Progesterone	
Manidipa Gupta and Amar Chatterjee	407
Effects of Monothioglycerol, Alpha-Chlorohydrin and 5-Thio-D-Glucose on the Fertility of Male Hamster	
R.P. Das and R. Yanagimachi	413
Specific Inhibition of Spermatozoal Energy Metabolism by Oxidized Spermine	
Pirkko Pulkkinen.	423
Reversal of Sterilization in the Male and Female: Report of a Workshop	
Gerald I. Zatuchni and John J. Sciarra	435
Conjugated Estrogen as a Post-Ovulatory Interceptive	
Morris Notelovitz and David Sayre Bard	443
Evaluation of a Single Dose Schedule of 15 (S) 15 Methyl PGF ₂ Alpha Methyl Ester Suppository for the Termination of 10-14 Weeks of Pregnancy	
G. Kinra, N. Agarwal, K.T. Jagannath and V. Hingorani	455
Preclinical Evaluation of Intrauterine Progesterone as a Contraceptive Agent.	
I. Local Contraceptive Effects and Their Reversal	
R. Hudson, P. Hemphill, S.A. Tillson	465
Preclinical Evaluation of Intrauterine Progesterone as a Contraceptive Agent.	
II. Possible Mechanisms of Action	
S.A. Tillson, R. Hudson, D. Swisher and P. Leong.	475
Preclinical Evaluation of Intrauterine Progesterone as a Contraceptive Agent.	
III. Embryology and Toxicology	
R. Hudson, B.B. Pharriss, S.A. Tillson and F. Reno.	489

CONTRACEPTION

June 1978

Volume 17, Number 6

Vitamin E Status of Young Women on Combined-Type Oral Contraceptives C.C. Tangney and J.A. Driskell	499
Bacteriologic Culture Results Obtained Before and After Elective Midtrimester Urea Abortion R.T. Burkman, M.R. Spence, M.F. Atienza and T.M. King	513
Phospholipid Analysis in Testis-Epididymis Complex After Alpha- Chlorohydrin Administration N.R. Kalla and B. Singh	523
No Increase of the Fibrinolytic Activity of the Human Endometrium by Progesterone-Releasing IUD (Progestasert®) P. Liedholm, N.-O. Sjöberg, K. Srivastava and B. Åstedt	531
Inhibition of Ovulation in Women by Chronic Treatment With a Stimulatory LRH Analogue — A New Approach to Birth Control? S.J. Nillius, C. Bergquist and L. Wide	537
Pregnancy Mare's Serum Gonadotropin: V. Indomethacin or Cortisone and the Reversal of Antifertility Efficacy of Pregnancy Mare's Serum Gonadotropin T. Gupta and A. Chatterjee	547
Fertility Inhibition by Intraoviductal Copper Beads in Rabbits S. Quijada, X. Soza and H.B. Croxatto	553
Is Development of Pelvic Inflammatory Disease in Women Using Intra-Uterine Device Equal Regardless of Parity? A One Year Follow-up Study S. Osser, B. Gullberg, P. Liedholm and N.-O. Sjöberg	563
Determination of Plasma Concentrations of d-Norgestrel During a One Year Follow-up in Women With a d-Norgestrel-Releasing IUD C.G. Nilsson, T. Luukkainen and P. Lähteenmäki	569
Letter to the Editor	575
Announcements	583
Author Index for Volume 17.	589
Subject Index for Volume 17.	593

CONTRACEPTION is published monthly by Geron-X, Inc.
Box 1108, Los Altos, California 94022, USA.

© 1978, Geron-X, Inc.

Two Volumes per year

Personal Subscription	\$ 60
Institutional Subscription	\$100
Add \$7 for surface postage outside USA	
Add \$16 for airmail USA. Add \$36 for airmail outside USA	

Second-class postage paid at Los Altos, Calif. 94022, and at additional mailing office.



INDEX TO VOLUME 18

AUTHOR INDEX

- Agarwal, N., 593
 Alvarez, F., 151
 Amtayakul, K., 253
 Andrade, A.T.L., 191
 Atkinson, L.E., 367
 Austin, F., 485
 Back, D.J., 127
 Barnes, G., 577
 Basu, R., 225
 Bates, M.W., 127
 Beck, L.R., 497
 Beckman, L.J., 7
 Benjamin, A., 59
 Bernstein, G.S., 485
 Birk, B.S., 121
 Birk, S.A., 121
 Bölk, M., 607
 Brache, V., 151
 Breckenridge, A.M., 127
 Bremme, K., 551
 Brenner, P.F., 615
 Buhi, W.C., 121
 Bye, P.G.T., 1, 535
 Bygdeman, M., 551
 Cameron, J., 577
 Carter, G., 295
 Cates, W., Jr., 561
 Cedillo, J.R., 271
 Chandra, H., 233
 Chapekar, A., 59
 Chatterjee, A., 225
 Chaudhury, R.R., 137
 Choudhury, S.D., 641
 Connell, K.G., 571
 Corbin, A., 105
 Corrales, E.S., 271
 Coutinho, E., 315, 335, 411
 Crawford, F.E., 127
 Croxatto, H.B., 315, 335,
 429, 441
 Culver, R.M., 239
 Das, C., 35, 51, 71
 da Silva, A.R., 315, 335
 Diaz, J., 429
 Diaz, S., 315, 335, 429, 441
 Domenzain, M.E., 271
 Dubey, S.K., 23, 59
 Dumbaugh, V.A., 121
 Dusitsin, N., 137
 Elder, M., 1, 535
 Faundes, A., 151, 315, 335, 355
 Fenoglio, C.M., 459
 Fitzpatrick, R.W., 477
 Fotherby, K., 1, 535
 Fox, E.J., 507
 Fuchs, F., 137
 Gentzschein, E.K., 615
 Gillmer, M.D.G., 507
 Gioia, I.A., 277
 Giwa-Osagie, O.F., 517
 Goebelsmann, U., 615
 Gray, R., 137
 Green, K., 551
 Grossman, R., 137
 Guerra, M.O., 191
 Gupta, P.D., 91
 Hafez, E.S.E., 105
 Hahn, D.W., 239
 Hahnenberger, R., 171
 Haspels, A.A., 635
 Hatcher, R.A., 163, 561
 Hew, L., 315, 335
 Hingorani, V., 35, 593
 Holma, P., 315, 335
 Hoogen, H., 607
 Houser, B.B., 7
 Howard, G., 1, 535
 Israngkum, C., 137
 Jackanicz, T.M., 395
 Jackson, H., 477
 Jacobs, H.S., 507
 Jain, A., 315, 335

CONTRACEPTION

INDEX TO VOLUME 18


AUTHOR INDEX (CONTINUED)

- Jamal, K., 593
 Jaszczak, S., 105
 Johansson, E.D.B., 171
 Kaplay, S.S., 287
 Kim-Parley, R.J., 561
 Koch, O.R., 277
 Kraft, L.A., 239
 Kulkarni, P.P., 543
 Kumar, S., 35
 Lähteenmäki, P., 201
 Laumas, K.R., 593
 Laumas, V., 593
 Lencioni, L.J., 277
 Loewenstein, R., 163
 Lövgren, T., 181
 Lowry, S.L., 497
 Lundberg, B., 181
 Luukkainen, T., 201, 451
 Mahan, C.S., 121
 Malaviya, B., 233
 Malik, B.K., 593
 Manchanda, P.K., 641
 Mattos, C.E.R., 315, 335
 McDonald, O., 315, 335
 Measham, A.R., 163
 Millen, A., 485
 Mishell, D.R., Jr., 615
 Mohini, P., 59
 Montes de Oca, V., 151
 Moo Young, A.J., 367
 Nash, H.A., 315, 335, 367, 395
 Nath, I., 91
 Neuwirth, R.S., 459
 Newton, J., 577
 Newton, J.R., 517
 Newton, P., 577
 Nielsen, N.C., 315, 335
 Nieschlag, E., 607
 Nigam, S.C., 233
 Nilsson, C.G., 451
 Nilsson, S., 469
 Nuwayser, E.S., 459
 Nygren, K.-G., 469
 Ohman, L., 171
 Onthuan, Y., 137
 Orme, M. L'E., 127
 Ortiz, A., 615
 Ory, H.W., 561
 Osler, M., 315, 335
 Patel, K.L., 543
 Pavez, M., 429, 441
 Peluso, J., 105
 Pettersson, K., 181
 Polidoro, J.P., 239
 Poulson, A.M., Jr., 295
 Prianishnikov, V.A., 213
 Punnonen, R., 181
 Quinteros, E., 429
 Raghavan, S.V., 23
 Ramakrishnan, S., 35, 51, 71
 Ramanadham, M., 287
 Ray, J., 59
 Richart, R.M., 459
 Robertson, D.N., 151, 315, 335, 367, 395, 429
 Rowe, P.H., 127
 Salahuddin, M., 23, 35
 Sanchez, F.A., 315, 335
 Saunders, D.M., 527
 Savage, J., 517
 Schuster, H., 607
 Segal, S., 315, 335
 Seth, U., 593
 Shahani, S.M., 543
 Shandilya, N.L., 105
 Shastri, N., 23, 59
 Shearman, R.P., 527
 Shrimanker, K., 1, 535
 Shuter, B., 527
 Siriwongse, T., 137
 Sivasomboon, B., 253
 Sivin, I., 151, 315, 335, 355
 Smiles, G., 127
 Smith, E., 127
 Somboonsuk, A., 137
 Spellacy, W.N., 121
 Stanczyk, F.Z., 615
 Stern, J., 315, 335, 355
 Sundaram, K., 571
 Talwar, G.P., 19, 23, 35, 51, 59, 71, 91

INDEX TO VOLUME 18

AUTHOR INDEX (CONTINUED)

Tejuja, S., 641	Wickings, E.J., 607
Thanangkul, O., 253	Wiese, J., 315, 335
Toivonen, J., 201	Williams, L.L., 315, 335
van den Bergh, A.S., 635	Zutshi, S., 233
Weiss, C., 163	



INDEX TO VOLUME 18

SUBJECT INDEX

- Abortion, febrile spontaneous and IUD, 561
- Activated adenosine triphosphatases, effect of oral contraceptives, 287
- Amenorrhea on the pill, 507
- Analysis of cases of missing IUD strings, 485
- Anti-hCG immunization, 19
- Anti-Pr- β -hCG-TT antibodies,
 - differential affinity for hCG and hLH, 23
 - discriminatory effect on gonadotropins, 35
- Antigon-F, comparative controlled trial in Thailand, 137
- Association constants, anti-Pr- β -hCG-TT antibodies for hCG and hLH, 23
- Barrier methods, nurse specialists in family planning clinic, 577
- Binding of estrogen to myometrial estrogen binding protein, effect of Cu^{2+} ions, 181
- Biological activity of gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
- Blood pressure, effect of subdermal implants, 335
- Body weight, effect of subdermal implants, 335
- Capsules, silastic,
 - release of steroids and resulting plasma levels, 395
 - steroid release, 367
- Carrier protein preimmunization, immunogenicity of hapten-protein conjugates (rabbit, monkey), 571
- α -Chlorohydrin phosphate isomer, effect on glyceraldehyde-3-phosphate dehydrogenase, 477
- Chloroquine, chemical occlusion of oviducts (monkey), 233
- Cholesterol, effect of oral R2323, 121
- Cholesterol as a matrix for controlled-release of progesterone (baboon), 497
- Choroid plexus, immunofluorescence and electron microscopic studies after immunization with Pr- β -hCG-TT (monkey), 91
- Clinical chemistry, treatment with progestogen implants, 441
- Clinical experience, d-norgestrel-releasing IUD, 451
- Clinical experience with implant contraception, 411
- Clinical trial,
 - subdermal implants containing norgestrienone, 429
 - testosterone undecanoate for male fertility control, 607
- Combined oral contraceptive,
 - comparative study of synthetic vs. natural estrogen, 527
 - failure of withdrawal bleeding, 507
- Comparative clinical trial, R-2323 and levonorgestrel subdermal implants, 151
- Comparative controlled trial in Thailand of three IUDs, 137

CONTRACEPTION

- Comparative study on combination oral contraceptives, synthetic vs. natural estrogen, 527
- Concept of stem cells, 213
- Confirmation of early pregnancy, use of radioreceptor test for HCG, 543
- Contraception with long acting subdermal implants, 315, 335, 355
- Contraceptive effects of native plants (rat), 191
- Contraceptive perceptions and usage among women, 7
- Contraceptive vaginal rings (CVR),
 levonorgestrel, 395
 norgestrel-estradiol, 201
 pituitary and gonadal function, 201
 release of steroids and resulting plasma level, 395
- Controlled-release of progesterone, cholesterol as a matrix (baboon), 497
- Copper IUD, TCu 200, compared to subdermal implants, 315, 335, 355
- Cu²⁺ ions, effect on binding of estrogen to myometrial estrogen binding protein, 181
- CVR (contraceptive vaginal rings)
- Detection of ovulation, change in finger-finger electro-potential readings, 295
- Diaphragm, perceptions and usage among women, 7
- Differences in activity of antisera raised against total gonadotropins vs. Pr- β -hCG-TT, 59
- Differential affinity of anti-Pr- β -hCG-TT antibodies for hCG and hLH, 23
- Discontinuation, injectable norethisterone oenanthate, 517
- Discriminatory activity on gonadotropins, antisera raised against total gonadotropins vs. Pr- β -hCG-TT, 59
- Discriminatory effect of anti-Pr- β -hCG-TT antibodies on gonadotropins, 35
- Early first trimester pregnancy interruption, single vaginal 15-methyl-PGF₂ α -methyl ester, 551
- Early pregnancy confirmation, use of radioreceptor test for HCG, 543
- Electron microscopic studies, immunization with Pr- β -hCG-TT (monkey), 91
- Electropotential difference in finger-finger contact, detection of ovulation, 295
- Endometrial epithelium, model of functional-morphological structure, 213
- Erythrocyte Na⁺ and K⁺, effect of oral contraceptives, 287
- Estradiol and estriol vs. ethinyl estradiol, combined oral contraceptive, 527
- Estrogen, effect of Cu²⁺ ions on binding to myometrial estrogen binding protein, 181
- Estrogen binding protein in myometrial cytosol, effect of Cu²⁺ ions on binding of estrogen, 181
- Estrogen in combination oral contraceptives, synthetic vs. natural, 527

- Ethinyl estradiol,
 - metabolism by everted sacs of ileum (rat), 127
 - plasma level after oral administration, 469
 - radioimmunoassay of plasma, 469
- Ethinyl estradiol vs. estradiol and estriol, combined oral contraceptive, 527
- Everted sacs of ileum, metabolism of ethynylestradiol and norethindrone (rat), 127
- Extra-amniotic prostaglandins for termination of pregnancies, 641
- Eye, topical administration of norethindrone and progesterone (monkey), 171
- Failure of withdrawal bleeding, combined oral contraceptive therapy, 507
- Fallopian tubes, intratubal devices (monkey), 459
- Family planning clinic, nurse specialists, 577
- Febrile spontaneous abortion and IUD, 561
- Fertility, effect of intravas device (rabbit), 239
- Functional-morphological model of structure of endometrial epithelium, 213
- Glucose, level in blood after oral R2323, 121
- Glyceraldehyde-3-phosphate dehydrogenase, effect of α -chloro-hydrin phosphate isomer, 477
- Gonadal function, use of norgestrel-estradiol CVR, 201
- Hapten-protein conjugates, effect of preimmunization with carrier protein (rabbit, monkey), 571
- hCG and hLH, differential affinity of anti-Pr- β -hCG-TT antibodies, 23
- hCG and hLH injections, progesterone level during luteal phase after immunization with Pr- β -hCG-TT (monkey), 51
- hCG and LH neutralization, Pr- β -hCG-TT vs. total gonadotropins antisera, 59
- hCG challenge, nature of immune complexes formed after immunization with Pr- β -hCG-TT (monkey), 71
- HCG radioreceptor test, 543
- Hemoglobin level, effect of subdermal implants, 335
- Hepatic function, effects of quinesterol (rat), 277
- High risk population, minilaparotomy as a primary interval sterilization procedure, 271
- Histology of reproductive tract, effect of intravas device (rabbit), 239
- Identification of IUD, do women know which they are wearing, 163
- Immune complexes formed, immunization with Pr- β -hCG-TT challenged with hCG (monkey), 71
- Immunization, anti-hCG, 19
- Immunofluorescence studies, immunization with Pr- β -hCG-TT (monkey), 91
- Immunogenicity of hapten-protein conjugates, preimmunization against carrier protein (rabbit, monkey), 571
- Implant, progesterone released from cholesterol pellets (baboon), 497

CONTRACEPTION

- Injectable contraception, nurse specialists in family planning clinic, 577
- Injectable contraceptive, medroxyprogesterone acetate, 253
- Injectable norethisterone oenanthate,
 - occurrence of ovulation, 535
 - study of patients discontinuing, 517
- Injections of norethisterone oenanthate, plasma level of norethisterone, 1
- Insulin, effect of oral R2323, 121
- International clinical trial, subdermal implants, 315, 335, 355
- Interval sterilization, minilaparotomy in high risk population, 271
- Intra-amniotic prostaglandins for termination of pregnancies, 641
- Intraamniotic sulprostone, second trimester pregnancy termination, 635
- Intratubal device, evaluation of polymer flock and metal alloy devices (monkey), 459
- Intrauterine device (IUD),
 - analysis of cases of missing strings, 485
 - Antigon-F, comparative trial, 137
 - comparative controlled trial in Thailand, 137
 - do women know which they are wearing, 163
 - febrile spontaneous abortion, 561
 - Lippes loop C, comparative trial, 137
 - d-norgestrel-releasing, 451
 - nurse specialists in family planning clinic, 577
 - perceptions and usage among women, 7
 - TCu 200, compared to subdermal implants, 315, 335, 355
 - Ypsilon, comparative trial, 137
- Intravas device,
 - effect on fertility (rabbit), 239
 - effect on histology of reproductive tract, 239
 - effect on sperm output (rabbit), 239
- Intravas device studies (rabbit), 239
- Isomer of α -chlorohydrin phosphate, effect on glyceraldehyde-3-phosphate dehydrogenase, 477
- IUD (intrauterine device)
- Kidney, immunofluorescence and electron microscopic studies after immunization with Pr- β -hCG-TT (monkey), 91
- Lactating women, serum level of norethindrone after norethindrone acetate implant, 593
- Levonorgestrel (d-norgestrel),
 - comparative clinical trial with subdermal implants, 151
 - effects of subdermal implants, 335
 - release from sustained release dosage forms and plasma level, 395
 - release rate from silastic capsules and rods, 367
 - subdermal implants, 315, 355
- LH, effect on serum level by LH-RH peptide antagonist (monkey), 105

- LH-RH (luteinizing hormone-releasing hormone)
- LH-RH peptide antagonist (Wy-18,185),
 - effect on menstrual cycle (monkey), 105
 - effect on ovulation (monkey), 105
 - effect on serum LH (monkey), 105
- Lippes loop C, comparative controlled trial in Thailand, 137
- Luteal phase progesterone level, hLH and hCG after immunization with Pr- β -hCG-TT (monkey), 51
- Luteinizing hormone-releasing hormone (LH-RH)
- Lynestrenol, clinical experience with implant contraception, 411
- Male fertility control,
 - intravas device studies (rabbit), 239
 - testosterone undecanoate, 607
- Medroxyprogesterone acetate, vitamin and trace mineral metabolism, 253
- Megestrol acetate,
 - clinical experience with implant contraception, 411
 - release from sustained release dosage forms and plasma levels, 395
 - release rate from silastic capsules and rods, 367
- Menstrual bleeding patterns, long acting contraceptive implants, 355
- Menstrual cycle, effect of LH-RH peptide antagonist (monkey), 105
- Menstrual pattern disturbance, effect of subdermal implants, 335
- Metabolism of ethynylestradiol and norethindrone by everted sacs of ileum (rat), 127
- Metal alloy, intratubal device (monkey), 459
- 15-Methyl-PGF₂ α -methyl ester, single vaginal administration, 551
- Minilaparotomy, primary interval sterilization procedure in high risk population, 271
- Missing IUD strings, analysis of cases, 485
- Mode of action of prostaglandins, 225
- Model of functional-morphological structure of endometrium, 213
- Multicentric trial, intra- and extra-amniotic prostaglandins for termination of pregnancies, 641
- Multiple injections of norethisterone oenanthate, plasma level of norethisterone, 1
- Myometrial estrogen binding protein, effect of Cu²⁺ ions on binding of estrogen, 181
- (Na⁺,K⁺) and (Mg⁺⁺, Ca⁺⁺) activated adenosine triphosphatases, effect of oral contraceptives, 287
- Native plants, contraceptive effects (rat), 191
- Natural vs. synthetic estrogen, comparative study on combination oral contraceptives, 527
- Nature of immune complexes formed, immunization with Pr- β -hCG-TT on challenge with hCG (monkey), 71
- Neutralization of biological activity of gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
- Neutralization of hCG and LH action, antisera raised against total gonadotropins vs. Pr- β -hCG-TT, 59

CONTRACEPTION

- Norethandrolone, release rate from silastic capsules and rods (rat), 367
- Norethindrone,
 - clinical experience with implant contraception, 411
 - metabolism by everted sacs of ileum (rat), 127
 - radioimmunoassay, 593, 615
 - release rate from silastic capsules and rods, 367
 - serum concentration following oral norethindrone-containing contraceptive, 615
 - serum level in lactating women after norethindrone acetate implant, 593
 - topical administration in eye and nose (monkey), 171
- Norethindrone-containing oral contraceptive, serum norethindrone concentrations, 615
- Norethindrone acetate, release rate from silastic capsules and rods (rat), 367
- Norethindrone acetate and natural vs. synthetic estrogen, combined oral contraceptive, 527
- Norethisterone oenanthate, plasma level of norethisterone, 1
- Norethisterone oenanthate as injectable contraceptive, occurrence of ovulation, 535
 - study of patients discontinuing, 517
- Norethisterone plasma levels, after injections of norethisterone oenanthate, 1
- d-Norgestrel (levonorgestrel),
 - clinical experience with implant contraception, 411
 - effects on metabolic parameters of subdermal implants, 441
- d-Norgestrel plasma concentrations, d-norgestrel-releasing IUD, 451
- Norgestrel-estradiol CVR, pituitary and gonadal function, 201
- d-Norgestrel-releasing IUD,
 - clinical experience, 451
 - plasma d-norgestrel concentrations, 451
- Norgestrienone (17 α -ethynyl-17-hydroxy-estra-4,9,11-triene-3-one, R 2010),
 - clinical experience implant contraception, 411
 - clinical trial with subdermal implants, 429
 - effects of subdermal implants, 335
 - effects on metabolic parameters of subdermal implants, 441
 - release from sustained release dosage forms and plasma level, 395
 - release rate from silastic capsules, 367
 - subdermal implants, 315, 355
- Nose, topical administration of norethindrone and progesterone (monkey), 171
- Nurse specialists in family planning clinic, 577
- Occlusion of oviducts, use of chloroquine (monkey), 233
- Oral administration of ethinyl estradiol, plasma levels, 469
- Oral combination contraceptive therapy, failure of withdrawal bleeding, 507
- Oral combination contraceptives, comparative study of synthetic vs. natural estrogen, 527

- Oral contraception, nurse specialists in family planning clinic, 577
- Oral contraceptive,
 - effect on (Na^+ , K^+) and (Mg^{++} , Ca^{++}) activated adenosine triphosphatases, 287
 - norethindrone-containing, 615
- Oral weekly contraceptive, R2323, 121
- Ovarian function, effect of injectable norethisterone oenanthate, 535
- Oviduct, chemical occlusion with chloroquine (monkey), 233
- Ovulation,
 - effect of LH-RH peptide antagonist (monkey), 105
 - occurrence during injectable norethisterone oenanthate, 535
- Ovulation detection, change in finger-finger electropotential readings, 295
- Perceptions and usage of contraceptives among women, 7
- PG (prostaglandin)
- $\text{PGF}_2\alpha$ -induced premature labor, involvement of progesterone (rat), 225
- Pill, perceptions and usage among women, 7
- Pituitary, immunofluorescence and electron microscopic studies after immunization with Pr- β -hCG-TT (monkey), 91
- Pituitary function, use of norgestrel-estradiol CVR, 201
- Pituitary gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
- Placental gonadotropins, effect of anti-Pr- β -hCG-TT antibodies, 35
- Plants, contraceptive effects (rat), 191
- Plasma Na^+ and K^+ , effect of oral contraceptives, 287
- Polymer flock, intratubal device (monkey), 459
- Pr- β -hCG-TT antibodies,
 - differential affinity for hCG and hLH, 23
 - discriminatory effect on gonadotropins, 35
- Pr- β -hCG-TT immunization,
 - immunofluorescence and electron microscopic studies (monkey), 91
 - nature of immune complexes formed on challenge with hCG (monkey), 71
 - progesterone level after hLH and hCG during luteal phase (monkey), 51
- Pr- β -hCG-TT vs. total gonadotropins antisera, neutralization of hCG and LH action, 59
- Pregnancy confirmation, use of radioreceptor test for HCG, 543
- Preimmunization with carrier protein, immunogenicity of hapten-protein conjugates (rabbit, monkey), 571
- Progesterone,
 - involvement in initiation of $\text{PGF}_2\alpha$ -induced premature labor (rat), 225

CONTRACEPTION

- release from implanted cholesterol pellets (baboon), 497
- topical administration in eye and nose (monkey), 171
- Progesterone level after hLH and hCG during luteal phase, immunization with Pr- β -hCG-TT (monkey), 51
- Progesterone-cholesterol pellets (baboon), 497
- Progestin-estrogen combination, clinical experience with implant contracepton, 411
- Prostaglandin (PG),
 - intra- and extra-amniotic for pregnancy termination, 641
 - 15-Me-PGF₂ α , 641
 - 15-methyl-PGF₂ α -methyl ester, 551
 - PGF₂ α
 - possible mode of action, 225
 - sulprostone, 635
- Quinestrol (3-cyclopentyl ether ethynil estradiol),
 - effect on hepatic function (rat), 277
- R-1364, clinical experience with implant contraception, 411
- R2323 (13 β -ethyl-17 α -ethynyl-17-hydroxy-gona-4,9,11-trien-3-one)
 - clinical experience with implant contraception, 411
 - comparative clinical trial with subdermal implants, 151
 - effect on blood glucose level, 121
 - effect on cholesterol level, 121
 - effect on insulin level, 121
 - effect on triglyceride level, 121
 - effects on metabolic parameters of subdermal implants, 441
- R2323 (17 β -hydroxy-17 α -ethynyl-18-methyl-4,9,11-estriene-3-one),
 - release rate from silastic capsules and rods, 367
- R-5020 (17 α -21-dimethyl-19-norpregna-4,9-dien-3,20-dione),
 - release rate from silastic capsules (rat), 367
- Radioimmunoassay,
 - norethindrone, 593, 615
 - plasma levels of ethinyl estradiol, 469
- Radioreceptor test for HCG, 543
- Reproductive tract histology, effect of intrav device (rabbit), 239
- Rods, silastic,
 - release of steroids and resulting plasma level, 395
 - steroid release, 367
- Second trimester pregnancy termination, intraamniotic sulprostone, 635
- Silastic capsules and rods, steroid release, 367
- Single vaginal administration, 15-methyl-PGF₂ α -methyl ester, 551
- Sperm output, effect of intravas device (rabbit), 239
- Spontaneous abortion, use of IUD, 561
- ST 1435 (16-methylene-17 α -acetoxy-19-norpregn-4-en-3,20-dione),
 - clinical experience with implant contraception, 411
 - release rate form silastic capsules, 367

CONTRACEPTION


- Stem cells, concept of functional-morphological structure of endometrial epithelium, 213
- Sterilization, minilaparotomy in high risk population, 271
- Subdermal implants,
analysis of menstrual bleeding patterns, 355
clinical experience, 411
clinical trial with norgestrienone, 429
comparative clinical trial of R-2323 and levonorgestrel, 151
effective and acceptable contraceptive modality, 315
effects in clinical trials, 335
effects on metabolic parameters, 441
levonorgestrel, 315, 335, 355, 367, 395
lynestrenol, 411
measured effects, 335
megestrol acetate, 367, 395, 411
norethandrolone, 367
norethindrone, 367, 411
norethindrone acetate, 367, 593
d-norgestrel, 411, 441
norgestrienone, 315, 335, 355, 367, 395, 411, 429, 441
perceived effects, 335
progestin-estrogen combinations, 411
R-1364, 411
R2323, 367, 411, 441
R-5020, 367
release of steroids and resulting plasma level, 395
serum level of norethindrone in lactating women, 593
ST.1435, 367, 411
steroid release, 367
testosterone, 367
testosterone propionate, 367
- Subjects' impressions of changes, effect of subdermal implants, 335
- Sulprostone (16-phenoxy- ω -17,18,19,20-tetranor-PGE₂-methyl-sulfonamide, SHB 286)
intraamniotic administration for second trimester pregnancy termination, 635
- Sulprostone with calcium gluconate, second trimester pregnancy termination, 635
- Sulprostone with oxytocin, second trimester pregnancy termination, 635
- Suppository, single 15-methyl-PGF₂ α -methyl ester, 551
- Synthetic vs. natural estrogen, comparative study on combination oral contraceptives, 527
- Testosterone, release rate from silastic capsules and rods, 367
- Testosterone propionate, release rate from silastic rods (rat), 367
- Testosterone undecanoate, clinical trial for male fertility control, 607
- Topical administration, norethindrone and progesterone in eye and nose (monkey), 171

CONTRACEPTION

- Total gonadotropins vs. Pr- β -hCG-TT antisera, neutralization of hCG and LH action, 59
- Trace mineral metabolism, use of medroxyprogesterone acetate, 253
- Triglyceride, effect of oral R2323, 121
- Type of IUD, do women know which they are wearing, 163
- Usage and perceptions of contraceptives among women, 7
- Use-related closures, injectable norethisterone oenanthate, 517
- Vaginal administration, single 15-methyl-PGF₂ α -methyl ester, 551
- Vasectomy, perceptions and usage among women, 7
- Vitamin metabolism, use of medroxyprogesterone acetate, 253
- Weekly oral contraceptive, R2323, 121
- Withdrawal bleeding, failure during combined oral contraceptive therapy, 507
- Wy-18,185 (D-(PHE)²-D-(ALA)⁶-LH-RH)
- Ypsilon, comparative controlled trial in Thailand, 137

Volume 18 1978
July - December
ISSN 0010 - 7824

CONTRACEPTION



DANIEL R. MISHELL, Jr., M.D.—Editor

BOARD OF ASSOCIATE EDITORS

Wendy Baldwin, Ph.D.
Behavioral Sciences Branch
Center for Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Gerald S. Bernstein, Ph.D., M.D.
Associate Professor
Department of Obstetrics and
Gynecology
USC School of Medicine
Los Angeles, California 90033

M. C. Chang, Ph.D., Sc.D.
Senior Scientist
Worcester Foundation for
Experimental Biology
Shrewsbury, Massachusetts 01545

Philip A. Corfman, M.D.
Director of Population Research
National Institute of Child Health
and Human Development
Bethesda, Maryland 20014

Uwe Goebelsmann, M.D.
Director of the Reproductive
Endocrinology Laboratory
Women's Hospital
1240 North Mission Road
Los Angeles, California 90033

Joseph W. Goldzieher, M.D.
Director, Division of Clinical
Sciences
Southwest Foundation for
Research and Education
San Antonio, Texas 78228

Roy O. Greep, Ph.D.
Director
Laboratory of Human Reproduction
& Reproductive Biology
Harvard Medical School
45 Shattuck Street
Boston, Massachusetts 02115

Roy Hertz, M.D., Ph.D.
Research Professor
Departments of Pharmacology
and Obstetrics and Gynecology
George Washington University
Medical Center
Washington, D.C. 20037

William D. Odell, M.D.
Professor and Chairman
Department of Medicine
Harbor General Hospital
U.C.L.A. School of Medicine
Torrance, California 90509

C. Alvin Paulsen, M.D.
Professor of Medicine
Department of Medicine
University of Washington
School of Medicine
Seattle, Washington 98114

John J. Sciarra, M.D., Ph.D.
Chief of Staff
Prentice Women's Hospital and
Maternity Center
333 East Superior St.
Chicago, Illinois 60611

Sheldon Segal, Ph.D.
Director, Biomedical Division
The Population Council
Rockefeller University
York Avenue and 66th Street
New York, New York 10021

William N. Spellacy, M.D.
Professor and Chairman
Department of Obstetrics and
Gynecology
The University of Florida
College of Medicine
Gainesville, Florida 32610

Howard J. Tatum, Ph.D., M.D.
Associate Director
Biomedical Division
The Population Council
The Rockefeller University
New York, New York 10021

Corresponding Editors for CONTRACEPTION

Eisimar Coutinho, M.D.
Professor
Department of Biochemistry and
Obstetrics
University of Bahia
Salvador, Bahia, BRAZIL

P. Giorgio Crosignani, M.D.
Professor Incaricato di
Endocrinologia Ginecologica
alla Facoltà di Medicina
Dell'Università di Milano
20122 Milano, ITALY
Via Comenda 12

Egon Diczfalusy, M.D.
Professor
Reproductive Endocrinology
Research Unit
Swedish Medical Research Council
Karolinska Sjukhuset
Stockholm 60, SWEDEN

J. Ferin, M.D.
Professor
Physiology of Human Reproduction
Research Unit
University of Louvain Hospital
Louvain, BELGIUM

Carlos Gual, M.D.
Instituto Nacional de la Nutrición
Hospital de Enfermedades de la
Nutrición
Av. San Fernando y
Viaducto Tlalpan
MEXICO 22, D.F., MEXICO

I. Hallbrecht, M.D.
Professor
Department of Obstetrics and
Gynecology
Tel Aviv University Medical School
Tel Aviv, ISRAEL

Prof. Dr. J. Hammerstein
Abt. Gynaek. Endokrinologie
Sterilität und Familienplanung
Freie Universität Berlin
Hindenburgdamm 30
1000 Berlin 45
FEDERAL REPUBLIC GERMANY

Professor Doctor A. A. Haspels
Department of Obstetrics and
Gynecology
Academic Hospital
University of Utrecht
Catharijnesingel 101
Utrecht, NETHERLANDS

Tapani Luukkainen, M.D.
Steroid Research Laboratory
University of Helsinki
Department of Medical Chemistry
Siltavuorenpenger 10 A
SF-00170 Helsinki 17, FINLAND

John R. Newton, M.B.
Department of Obstetrics and
Gynecology
King's College Hospital Medical
School
University of London
Denmark Hill
London, SE5 8RX
ENGLAND

Dr. M. R. N. Prasad
Professor of Zoology
University of Delhi
Delhi 7, INDIA

Dr. (Mrs.) Shanta S. Rao
Reproductive Physiology Unit
Indian Council of Medical Research
Seth G. S. Medical College
Parel, Bombay 12, INDIA

Rodney P. Shearman
Professor of Obstetrics and
Gynecology
The University of Sydney
Sydney 2006, NSW
AUSTRALIA

Sabita Tejuja, M.D.
Deputy Director General
Contraceptive Testing Unit
Indian Council of Medical Research
Ansari Nagar
Post Box 4508
New Delhi- 110016
INDIA

Martin P. Vessey, M.D.
Professor, University Department of
Social and Community Medicine
University of Oxford
8 Keble Road
Oxford, OX1 3 QN
ENGLAND

Juan Zanartu, M.D.
Associate Professor
Department of Experimental
Fertility
Universidad de Chile Clínica
Obstétrica
Hospital "Jose Joaquín Aguirre"
Casilla 6637
Santiago, CHILE

CONTRACEPTION

July 1978

Volume 18, Number 1

Plasma Levels of Norethisterone After Single and Multiple Injections of Norethisterone Oenanthate

K. Fotherby, G. Howard, K. Shrimanker, M. Elder and P.G.T. Bye..... 1

Examination of Contraceptive Perceptions and Usage Among Los Angeles County Women

B.B. Houser and L.J. Beckman..... 7

Anti-hCG Immunization. Introduction

G.P. Talwar..... 19

Differential Affinity of Anti-Pr- β -hCG-TT Antibodies for hCG and hLH

N. Shastri, S.K. Dubey, S.V. Raghavan, M. Salahuddin and G.P. Talwar..... 23

Discriminatory Effect of Anti-Pr- β -hCG-TT Antibodies on the Neutralization of the Biological Activity of Placental and Pituitary Gonadotropins

C. Das, G.P. Talwar, S. Ramakrishnan, M. Salahuddin, S. Kumar, V. Hingorani, E. Coutinho, H. Croxatto, E. Hemmingson, E. Johansson, T. Luukkainen, S. Shahani, K. Sundaram, H. Nash and S.J. Segal 35

Progesterone Levels in Monkeys Immunized with Pr- β -hCG-TT After Injection of hLH and hCG During Luteal Phase

S. Ramakrishnan, C. Das and G.P. Talwar..... 51

Differences Between the Discriminatory Activity of Antisera Raised Against the Total Gonadotropins and the Pr- β -hCG-TT for Neutralization of hCG and hLH Action

P. Mohini, T.N. Chapekar, A. Benjamin J. Raj, N. Shastri, S.K. Dubey and G.P. Talwar 59

Nature of Immune Complexes Formed in Rhesus Monkeys Immunized With Pr- β -hCG-TT on Challenge With hCG

S. Ramakrishnan, C. Das and G.P. Talwar..... 71

Immunofluorescence and Electron Microscopic Studies on Kidney, Choroid Plexus and Pituitary in Rhesus Monkeys Immunized With the Anti-hCG Vaccine Pr- β -hCG-TT

P.D. Gupta, I. Nath and G.P. Talwar..... 91

CONTRACEPTION is published monthly by Geron-X, Inc.
Box 1108, Los Altos, California 94022, USA.

© 1978, Geron-X, Inc.

Two Volumes per year

Personal Subscription \$ 60

Institutional Subscription \$100

Add \$7 for surface postage outside USA

Add \$16 for airmail USA. Add \$36 for airmail outside USA

Second-class postage paid at Los Altos, Calif. 94022, and at additional mailing office.

CONTRACEPTION

August 1978

Volume 18, Number 2

Effect of LH-RH Peptide Antagonist on Serum LH, Ovulation and Menstrual Cycle of Crab-Eating Macaque A. Corbin, S. Jaszczak, J. Peluso, N.L. Shandilya and E.S.E. Hafez.....	105
Blood Glucose, Insulin, Cholesterol and Triglyceride Levels in Women Treated for Six Months with the Weekly Oral Contraceptive R2323 W.N. Spellacy, C.S. Mahan, W.C. Buhi, V.A. Dumbaugh, and S.A. Birk.....	121
Ethinylestradiol and Norethindrone Metabolism by Everted Sacs of Rat Ileum D.J. Back, M.W. Bates, A.M. Breckenridge, F.E. Crawford, M.L'E. Orme, P.H. Rowe, G. Smiles and E. Smith.....	127
A Comparative Controlled Trial in Rural Thailand of Three Intrauterine Devices A. Somboonsuk, C. Israngkum, T. Siri Wongse, N. Dusitsin, Y. Onthuam, R.R. Chaudhury, F. Fuchs, R. Grossman and R. Gray.....	137
Comparative Clinical Trial of the Progestins R-2323 and Levonorgestrel Administered by Subdermal Implants F. Alvarez, D.N. Robertson, V. Montes de Oca, I. Sivin, V. Brache and A. Faundes.....	151
Do Women Know Which IUD They are Wearing? R.A. Hatcher, A.R. Measham, C. Weiss and R. Loewenstein.....	163
Topical Administration of Progestational Steroids in the Eye and Nose - A Rapid Absorption to the Blood L. Ohman, R. Hahnenberger and E.D.B. Johansson.....	171
Effect of Cu ²⁺ Ions on the Binding of Estrogen to the Human Myometrial Estrogen Binding Protein T. Lövgren, K. Pettersson, B. Lundberg and R. Punnonen	181
Contraceptive Effects of Native Plants in Rats M.O. Guerra and A.T.L. Andrade.....	191

Pituitary and Gonadal Function During the Use of Norgestrel-Estradiol Vaginal Rings Toivonen, J., Lähteenmäki, P. and Luukkainen, T.....	201
On the Concept of Stem Cell and a Model of Functional-Morphological Structure of the Endometrium Pranishnikov, V.A.....	213
The Possible Mode of Action of Prostaglandins: XIV Evidence of an Involvement of Progesterone in the Initiation of Prostaglandin $F_{2\alpha}$ -Induced Premature Labor in Rats Basu, R. and Chatterjee, A.....	225
Chemical Occlusion of Rhesus Monkey Oviducts With Chloroquine Chandra, H., Nigam, S.C., Zutshi, S. and Malaviya, B.....	233
Intravas Device Studies in Rabbits: II. Effects on Sperm Output, Fertility and Histology of the Reproductive Tract Kraft, L.A., Polidoro, J.P., Culver, R.M. and Hahn, D.W.....	239
Vitamin and Trace Mineral Metabolism in Medroxyprogesterone Acetate Users Amatayakul, K., Sivasomboon, B. and Thanangkul, O.....	253
Minilaparotomy as a Primary Interval Sterilization Procedure in a High Risk Population Domenzain, M.E., Corrales, E.S. and Cedillo, J.R.....	271
Effects of Quinestrol on Hepatic Function in the Rat Gioia, I., Lencioni, L.J. and Koch, O.R.....	277
Erythrocyte Membrane (Na ⁺ , K ⁺) and (Mg ⁺⁺ , Ca ⁺⁺) Activated Adenosine Triphosphatases in Women Using Oral Contraceptives - A Preliminary Report Kaplay, S.S. and Ramanadham, M.....	287
Detection of Ovulation by a Method of Change in Finger-Finger Electropotential Readings Poulson, A.M., Jr. and Carter, G.....	295
Announcements.....	309

Contraception With Long Acting Subdermal Implants: I. An Effective and Acceptable Modality in International Clinical Trials	
Coutinho, E., da Silva, A.R., Mattos, C.E.R., Nielsen, N.C., Osler, M., Wiese, J., Holma, P., Diaz, S., Croxatto, H.B., Sanchez, F.A., Faundes, A., Williams, L.L., Hew, L., McDonald, O., Segal, S., Nash, H., Robertson, D., Jain, A., Stern, J. and Sivin, I.	315
Contraception With Long Acting Subdermal Implants: II. Measured and Perceived Effects in International Clinical Trials	
Coutinho, E., da Silva, A.R., Mattos, C.E.R., Nielsen, N.C., Osler, M., Wiese, J., Holma, P., Diaz, S., Croxatto, H.B., Sanchez, F.A., Faundes, A., Williams, L.L., Hew, L., McDonald, O., Segal, S., Nash, H., Robertson, D., Jain, A., Stern, J. and Sivin, I.	335
Long Acting Contraceptive Implants: An Analysis of Menstrual Bleeding Patterns	
Faundes, A., Sivin, I. and Stern, J.	355
Steroid Release From Silastic Capsules and Rods	
Nash, H.A., Robertson, D.N., Moo Young, A.J. and Atkinson, L.E.	367
Release of Contraceptive Steroids From Sustained Release Dosage Forms and Resulting Plasma Levels	
Nash, H.A., Robertson, D.N. and Jackanicz, T.M.	395
Clinical Experience With Implant Contraception	
Coutinho, E.	411
Clinical Trials With Subdermal Implants Containing Norgestrienone	
Diaz, S., Pavez, M., Quinteros, E., Diaz, J., Robertson, D.N. and Croxatto, H.B.	429
Clinical Chemistry in Women Treated With Progestogen Implants	
Croxatto, H.B., Diaz, S. and Pavez, M.	441
Sustained Intrauterine Release of d-Norgestrel	
Luukkainen, T. and Nilsson, C.G.	451

CONTRACEPTION

November 1978

Volume 18, Number 5

Evaluation of Polymer Flock and Metal Alloy Intra-tubal Device in Pigtail Monkeys Richart, R.M., Neuwirth, R.S., Nuwayser, E.S. and Fenoglio, C.M.	459
Ethinyl Estradiol in Peripheral Plasma After Oral Administration of 30 µg and 50 µg to Women Nilsson, S. and Nygren, K.-G.	469
Effect of Racemic and S(+) α-Chlorohydrin-1-Phosphate on Glyceraldehyde-3-Phosphate Dehydrogenase in Relation to its Contraceptive Action Fitzpatrick, R.W., Jackson, H. and Dickinson, N.A.	477
Analysis of 100 Cases of Missing IUD Strings Millen, A., Austin, F. and Bernstein, G.S.	485
<i>In Vivo</i> Evaluation of Cholesterol as a Matrix for the Controlled-Release of Progesterone Beck, L.R. and Lowry, S.L.	497
Failure of Withdrawal Bleeding During Combined Oral Contraceptive Therapy: 'Amenorrhoea on the Pill' Gillmer, M.D.G., Fox, E.J. and Jacobs, H.S.	507
Norethisterone Oenanthate as an Injectable Contraceptive: A Study of Patients Discontinuing Treatment Giwa-Osagie, O.F., Savage, J. and Newton, J.R.	517
Comparative Studies on Two Combination Oral Contraceptives, One Containing Synthetic Estrogen, the Other "Natural" Estrogens Saunders, D.M., Shuter, B. and Shearman, R.P.	527
Occurrence of Ovulation in Women Receiving the Injectable Contraceptive Norethisterone Oenanthate Fotherby, K., Howard, G., Shrimanker, K., Elder, M. and Bye, P.G.T.	535
Use of a Radioreceptor Test for HCG in Women Practicing Contraception Shahani, S.M., Kulkarni, P.P. and Patel, K.L.	543

Interruption of Early Trimester Pregnancy by Single Vaginal Administration of 15-Methyl-PGF ₂ α -Methyl Ester Gr��n, K., Bygdeman, M. and Bremme, K.....	551
Febrile Spontaneous Abortion and the IUD Kim-Farley, R.J., Cates, W., Jr., Ory, H.W. and Hatcher, R.A.....	561
Immunogenicity of Hapten-Protein Conjugates in Rabbits and Monkeys Preimmunized Against the Carrier Protein Sundaram, K. and Connell, K.G.....	571
Nurse Specialists in Family Planning: The Results of a 3-Year Study Newton, J., Barnes, G., Cameron, J. and Newton, P.....	577
Radioimmunoassay of Norethindrone: Serum Levels of Norethindrone in Lactating Women After Insertion of a Single Silastic Implant Releasing Norethindrone Acetate Laumas, V., Malik, B.K., Jamal, K., Seth, U., Agarwal, N., Hingorani, V. and Laumas, K.R.....	593
Clinical Trial With Testosterone Undecanoate for Male Fertility Control Nieschlag, E., Hoogen, H., B��lk, M., Schuster, H. and Wickings, E.J.....	607
A Radioimmunoassay for Norethindrone (NET): Measurement of Serum NET Concentrations Following Ingestion of NET-Containing Oral Contraceptive Steroids Stanczyk, F.Z., Brenner, P.F., Mishell, D.R., Jr., Ortiz, A., Gentzschein, E.K.E. and Goebelsmann, U.....	615
Termination of Second Trimester Pregnancy With Intraamniotic Administration of 16-Phenoxy- ω -Tetranor-PGE ₂ -Methyl sulfonamide (SHB 286) Alone and Combined With Oxytocin and Calcium Gluconate van den Bergh, A.S. and Haspels, A.A.....	635
Use of Intra- and Extra-Amniotic Prostaglandins for the Termination of Pregnancies: Report of Multicentric Trial in India Tejuja, S., Choudhury, S.D. and Manchanda, P.K.....	641
Announcement.....	653
Author Index for Volume 18.....	655
Subject Index for Volume 18.....	659

